ProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Rhea-AI Summary

ProMIS Neurosciences (Nasdaq: PMN), a biotechnology company focused on developing therapeutics for neurodegenerative diseases, announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. CEO Neil Warma will present an overview of the company's antibody therapeutics targeting toxic misfolded proteins in diseases like Alzheimer's, ALS, and multiple system atrophy.

Key points:

• Presentation available on-demand from September 9, 2024, at 7:00 a.m. ET
• One-on-one meetings with investors scheduled for September 9-10, 2024
• Replay accessible for at least 30 days on the company's website

This event provides an opportunity for ProMIS to showcase its innovative approach to treating neurodegenerative diseases to potential investors and industry professionals.

CAMBRIDGE, Massachusetts and TORONTO, Ontario, Sept. 05, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, today announced that Neil Warma, Chief Executive Officer of ProMIS Neurosciences, will participate at the H.C. Wainwright 26^th Annual Global Investment Conference and will conduct one-on-one meetings from September 9 – 10, 2024.

Mr. Warma will deliver an overview of the Company’s pioneering antibody therapeutics that selectively target toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease, amyotrophic lateral sclerosis and multiple system atrophy (MSA) and will be available for virtual meetings with investors through the H.C. Wainwright conference platform.

The company’s presentation will be available to view on demand beginning Monday, September 9, 2024 at 7:00 a.m. Eastern Time by visiting the Events page of the Company’s website at www.promisneurosciences.com. The replay will be available for at least 30 days following the event.

About ProMIS Neurosciences Inc.

ProMIS Neurosciences Inc. is a clinical stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). The Company’s proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS™ and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. ProMIS has offices in Cambridge, Massachusetts and Toronto, Ontario.

For further information:

Visit us at www.promisneurosciences.com

Please submit media inquiries to info@promisneurosciences.com.

For Investor Relations, please contact:
Precision AQ (formerly Stern IR)
Anne Marie Fields, Managing Director
annemarie.fields@precisionaq.com
Tel. 212-362-1200

FAQ

When is ProMIS Neurosciences (PMN) presenting at the H.C. Wainwright Global Investment Conference?

ProMIS Neurosciences (PMN) will have an on-demand presentation available starting September 9, 2024, at 7:00 a.m. Eastern Time. The company will also conduct one-on-one meetings from September 9-10, 2024.

What will ProMIS Neurosciences (PMN) discuss in their presentation at the H.C. Wainwright conference?

CEO Neil Warma will present an overview of ProMIS Neurosciences' antibody therapeutics that target toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease, ALS, and multiple system atrophy (MSA).

How long will the replay of ProMIS Neurosciences' (PMN) presentation be available?

The replay of ProMIS Neurosciences' (PMN) presentation will be available for at least 30 days following the event on the company's website.

What is the focus of ProMIS Neurosciences' (PMN) research and development?

ProMIS Neurosciences (PMN) focuses on generating and developing therapeutics that target toxic misfolded proteins in neurodegenerative diseases, including Alzheimer's disease, ALS, and multiple system atrophy.